
In today’s briefing:
- Giant Biogene IPO: Strong Growth Prospects Offsets Short-Term Margin Concerns
- Yunsung F&C IPO Preview
Giant Biogene IPO: Strong Growth Prospects Offsets Short-Term Margin Concerns
- Giant Biogene Holding (GBH HK) designs, develops and manufactures professional skin treatment products with recombinant collagen as the key bioactive ingredient in China.
- The company has filed for an IPO on the Hong Kong Stock Exchange and plans to raise proceeds of around HK$500m.
- We remain positive on Biogene’s growth prospects as it operates in a growing market which should further benefit from regulatory tailwinds.
Yunsung F&C IPO Preview
- Yunsung F&C is a leading maker of materials mixing equipment that are used in the rechargeable battery production.
- The IPO price range is from 53,000 won to 62,000 won and offering amount is from 106 billion won to 124 billion won. The book building starts on 26 October.
- According to the bankers’ valuation, the expected IPO market cap range is from 423 billion won to 495 billion won.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars